Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.
作者信息
Volkmann Elizabeth R, Tashkin Donald P
机构信息
Department of Medicine David Geffen School of Medicine at UCLA Los Angeles, California.
出版信息
Am J Respir Crit Care Med. 2024 May 1;209(9):1067-1068. doi: 10.1164/rccm.202401-0246ED.
Abstract
摘要
相似文献
1
Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.
Am J Respir Crit Care Med. 2024 May 1;209(9):1067-1068. doi: 10.1164/rccm.202401-0246ED.
2
Treatment of systemic sclerosis.
Rheum Dis Clin North Am. 1996 Nov;22(4):893-907. doi: 10.1016/s0889-857x(05)70307-0.
3
Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations.
Ann Am Thorac Soc. 2024 Jan;21(1):12-16. doi: 10.1513/AnnalsATS.202309-760CME.
4
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203.
5
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR.
6
Systemic sclerosis-associated interstitial lung disease.
Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27.
7
[New developments in systemic sclerosis-associated interstitial lung disease].
Rev Med Suisse. 2020 Nov 18;16(715):2218-2223.
8
Systemic sclerosis related interstitial lung disease: What is the recommended treatment?
Reumatol Clin (Engl Ed). 2021 Oct;17(8):490. doi: 10.1016/j.reumae.2019.12.005.
9
[Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].
Rev Med Interne. 2022 Jun;43(6):365-374. doi: 10.1016/j.revmed.2021.12.003. Epub 2022 Feb 15.
10
Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma.
Rheum Dis Clin North Am. 2021 Nov;47(4):757-780. doi: 10.1016/j.rdc.2021.07.004. Epub 2021 Sep 2.
引用本文的文献
1
Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative Study.
CHEST Pulm. 2025 Jun;3(2). doi: 10.1016/j.chpulm.2025.100159. Epub 2025 Mar 24.
2
Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.
Curr Treatm Opt Rheumatol. 2025 Dec;11(1). doi: 10.1007/s40674-024-00221-7. Epub 2025 Jan 9.
3
Understanding Late-Onset Interstitial Lung Disease in Systemic Sclerosis: Implications for Clinical Practice and Trial Design.
Arthritis Rheumatol. 2025 Apr;77(4):380-382. doi: 10.1002/art.43053. Epub 2024 Dec 1.
本文引用的文献
1
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy.
ACR Open Rheumatol. 2023 Oct;5(10):547-555. doi: 10.1002/acr2.11598. Epub 2023 Aug 17.
2
Rare-disease researchers pioneer a unique approach to clinical trials.
Nat Med. 2023 Aug;29(8):1884-1886. doi: 10.1038/s41591-023-02333-4.
3
Designing clinical trials for rare diseases: unique challenges and opportunities.
Nat Rev Methods Primers. 2022 Mar 10;2(1). doi: 10.1038/s43586-022-00100-2. eCollection 2022 Dec.
4
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
Chest. 2023 Mar;163(3):586-598. doi: 10.1016/j.chest.2022.09.044. Epub 2022 Oct 14.
5
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
6
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28.
7
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.
8
Adaptive designs in clinical trials: why use them, and how to run and report them.
BMC Med. 2018 Feb 28;16(1):29. doi: 10.1186/s12916-018-1017-7.
9
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.
10
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
Zotero 插件